Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
暂无分享,去创建一个
H. Lan | K. Jin | L. Teng | Feilin Cao | Kuifeng He | Zhen-zhen Xu | N. Han | Guang-liang Li
[1] S. Eberhardt,et al. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] H. Lan,et al. Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases , 2011, PloS one.
[3] K. Jin,et al. Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection. , 2011, Hepato-gastroenterology.
[4] K. Jin,et al. Heterogeneity in primary tumors and corresponding metastases: could it provide us with any hints to personalize cancer therapy? , 2011, Personalized medicine.
[5] Zhongqi Li,et al. Heterogeneity in primary colorectal cancer and its corresponding metastases: a potential reason of EGFR-targeted therapy failure? , 2011, Hepato-gastroenterology.
[6] K. Jin,et al. Personalized cancer therapy using a patient-derived tumor tissue xenograft model: a translational field worthy of exploring further? , 2010, Personalized medicine.
[7] K. Jin,et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review , 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[8] K. Schaefer,et al. Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases , 2010, Clinical Cancer Research.
[9] P. Jänne,et al. Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] L. Mazzucchelli,et al. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant , 2009, British Journal of Cancer.
[11] P. Jänne,et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients , 2008, British Journal of Cancer.
[12] F. Meric-Bernstam,et al. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases , 2008, Cancer.
[13] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Marc Ladanyi,et al. Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases , 2008, Clinical Cancer Research.
[15] R. Berardi,et al. Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options , 2007, British Journal of Cancer.
[16] Inti Zlobec,et al. HER2 gene status in primary breast cancers and matched distant metastases , 2007, Breast Cancer Research.
[17] Silvia Benvenuti,et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.
[18] R. Hruban,et al. An In vivo Platform for Translational Drug Development in Pancreatic Cancer , 2006, Clinical Cancer Research.
[19] M. Loda,et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. , 2005, The Journal of molecular diagnostics : JMD.
[20] N. Sneige,et al. Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma , 2005, Cancer.
[21] Silvia Benvenuti,et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.
[22] R. Berardi,et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] P. Regitnig,et al. Change of HER‐2/neu status in a subset of distant metastases from breast carcinomas , 2004, The Journal of pathology.
[24] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[25] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] I. Bauerfeind,et al. Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients , 2004, Clinical Cancer Research.
[27] N. Personeni,et al. HER‐2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma , 2003, Cancer.
[28] D. Larsimont,et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] J. Luketich,et al. Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stage II non-small cell lung carcinoma: implications for the timing of lymph node metastasis and prognostic value. , 2002, Cancer research.
[30] H. Huynh,et al. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. , 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[31] T. H. van der Kwast,et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. , 2001, Cancer research.
[32] J. Isola,et al. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. , 2001, Cancer research.
[33] R. Perez-soler,et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] R. Henriksson,et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Vermeulen,et al. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. , 1999, The cancer journal from Scientific American.
[36] O. Vinante,et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. , 1997, Journal of the National Cancer Institute.